Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction.

[1]  R. Gibbons,et al.  Time to therapy and salvage in myocardial infarction. , 1998, Journal of the American College of Cardiology.

[2]  J. Golmard,et al.  Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. , 1998, Journal of the American College of Cardiology.

[3]  R. Gibbons,et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction : A quantitative review , 1997 .

[4]  J. Rawles,et al.  Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). , 1997, Journal of the American College of Cardiology.

[5]  B. Brodie.  When should patients with acute myocardial infarction be transferred for primary angioplasty? , 1997, Heart.

[6]  J. Berry,et al.  Timing and mechanism of death determined clinically after primary angioplasty for acute myocardial infarction. , 1997, The American journal of cardiology.

[7]  J. J. Griffin,et al.  A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second Primary Angioplasty in Myocardial Infarction (PAMI-II) Trial Investigators. , 1997, Journal of the American College of Cardiology.

[8]  W. Weaver,et al.  Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. , 1996, Circulation.

[9]  F Van de Werf,et al.  Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. , 1996, Journal of the American College of Cardiology.

[10]  R. M. Rubison,et al.  A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. , 1996, Journal of the American College of Cardiology.

[11]  B. Brodie.  Primary angioplasty in a community hospital in the USA. , 1995, British heart journal.

[12]  J. Berry,et al.  Benefit of late coronary reperfusion in patients with acute myocardial infarction and persistent ischemic chest pain. , 1994, The American journal of cardiology.

[13]  R. Califf,et al.  Six‐Month Clinical and Angiographic Follow‐up After Direct Angioplasty for Acute Myocardial Infarction: Final Results From the Primary Angioplasty Registry , 1994, Circulation.

[14]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[15]  P. Kudenchuk,et al.  Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. , 1993, JAMA.

[16]  S. Kaul,et al.  An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. , 1992, The New England journal of medicine.

[17]  B. Rutherford,et al.  Timing and mechanism of in-hospital and late death after primary coronary angioplasty during acute myocardial infarction. , 1990, The American journal of cardiology.

[18]  F. Harrell,et al.  Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. , 1990, Journal of the American College of Cardiology.

[19]  R. Califf,et al.  From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. , 1989, Journal of the American College of Cardiology.

[20]  M. Cohen,et al.  Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary end point findings of the Second Mount Sinai-New York University Reperfusion Trial. , 1989, Journal of the American College of Cardiology.

[21]  E. Braunwald,et al.  Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded? , 1989, Circulation.

[22]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[23]  Y. Ohtsuki,et al.  ISOLATION OF HTLV-I FROM CEREBROSPINAL FLUID OF A PATIENT WITH MYELOPATHY , 1986, The Lancet.

[24]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[25]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[26]  W. Rogers,et al.  Return of left ventricular function after reperfusion in patients with myocardial infarction: importance of subtotal stenoses or intact collaterals. , 1984, Circulation.

[27]  J. Lowe,et al.  The Wavefront Phenomenon of Ischemic Cell Death: 1. Myocardial Infarct Size vs Duration of Coronary Occlusion in Dogs , 1977, Circulation.

[28]  J. W. Kennedy,et al.  Left ventricular volume and mass from single-plane cineangiocardiogram. A comparison of anteroposterior and right anterior oblique methods. , 1970, American heart journal.

[29]  J. Wardrope,et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction. , 1999, Journal of accident & emergency medicine.

[30]  Bruce R. Brodie,et al.  Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction : In-hospital and 30-day results of the PAMI stent pilot trial , 1998 .

[31]  Grines.  Transfer of High-Risk Myocardial Infarction Patients for Primary PTCA. , 1997, The Journal of invasive cardiology.

[32]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[33]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[34]  B. Brodie,et al.  Outcomes of direct coronary angioplasty for acute myocardial infarction in candidates and non-candidates for thrombolytic therapy. , 1991, The American journal of cardiology.

[35]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[36]  M. Franzosi,et al.  [The Italian Group for the Study of Streptokinase in Myocardial Infarct: Analysis of intrahospital causes of death]. , 1987, Giornale italiano di cardiologia.

[37]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[38]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.